Infectious diseases, Anti-infectives, antimicrobials, antivirals, drug repurposing, repositioning, drug development, infectious diseases, respiratory diseases, small molecules, flu, RSV, hMPV, MERS

Signia Therapeutics has developed a breakthrough strategy to reposition rapidly & at low cost commercially available or shelved drugs (from proprietary libraries) in new anti-infectious indications, especially against respiratory viruses. Signia Therapeutic’s drug discovery platform is based on the analysis of transcriptomic signatures. This platform has demonstrated its potential with eight repurposed molecules, pre-clinically validated as new antivirals (flu, RSV, hMPV and MERS), protected by international patents, and available for out-license. One of the molecules repositioned by Signia Therapeutics is currently in Phase II clinical trial in severe flu, aiming to include 176 patients, with results expected mid-2020. Signia Therapeutics platform will continuously propose new drug candidates in infectious diseases.